17 Aug DHCPL for ACE-inhibitor/Angiotensin receptor blocker containing medicines
Posted at 12:48h
in
In collaboration with the South African Health Products Regulatory Authority (SAHPRA), Novartis SA (Pty) Ltd would like to inform you of a risk of acute kidney injury (AKI) in patients treated concomitantly with Angiotensin Converting Enzyme Inhibitors (ACEIs) /Angiotensin receptor blockers (ARBs) and fluoroquinolones.
2019 Oct
Download latest version
Document Number:
DHCPL
Version:
1
Date Updated:
11/10/2019
File Type:
pdf
Category:
Communication To Health Care Professionals